- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.11. | Novartis secures approval from FDA for Itvisma to treat SMA | ||
| 24.11. | GLP-1RA Alzheimer's hopes dashed after Novo Nordisk's semaglutide miss | ||
| 24.11. | Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club | ||
| 24.11. | Navigating the FDA's import operations for pharmaceuticals and biologics | ||
| 24.11. | Investors bet on newer technology and indications for CGTs | ||
| 24.11. | AstraZeneca to expand biomanufacturing in Maryland, US | ||
| 24.11. | Vaximm and BCME link on oral cancer immunotherapy platform | ||
| 21.11. | "Reckless and harmful": experts weigh in on CDC's autism-vaccine link stance | ||
| 21.11. | Early planning, outsourcing and digitalisation to break down CGT CMC barriers | ||
| 21.11. | Aspen closes $115m in Series C to advance Parkinson's cell therapy | ||
| 21.11. | Alvotech and Advanz announce EC approval for Gobivaz biosimilar | ||
| 20.11. | CPHI 2025: linker innovation paves the way for a wave of new ADCs | ||
| 20.11. | Merck KGaA eyes new Parkinson's disease assets with $3bn Valo partnership | ||
| 20.11. | Moderna to onshore drug product manufacturing to Massachusetts | ||
| 20.11. | Regeneron's Eylea franchise boosted by pair of FDA approvals | ||
| 20.11. | Novartis taps North Carolina as new manufacturing hub location | ||
| 20.11. | Pfizer and Tris agree with Texas over ADHD drug allegations | ||
| 20.11. | EC authorises Roche's Lunsumio SC for follicular lymphoma | ||
| 19.11. | Alkermes prevails over Lundbeck in Avadel bidding war | ||
| 19.11. | Arrowhead nets first commercial win as siRNA drug garners FDA approval | ||
| 19.11. | FDA approves AbbVie's Epkinly to treat follicular lymphoma | ||
| 19.11. | CSL to pump $1.5bn into US plasma supply chain | ||
| 19.11. | USPTO grants patent to Genprex's Reqorsa gene therapy | ||
| 19.11. | Insmed receives EC approval for Brinsupri to treat NCFB | ||
| 18.11. | Redefining clinical trials in oncology and rare diseases across the Europe |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .